Skip to Content

Disclaimer

Disclaimer
MDS makes every effort to publish accurate information on the website. "Google Translate" is provided as a free tool for visitors to read content in one's native language. Translations are not guaranteed to be 100% accurate. Neither MDS nor its employees assume liability for erroneous translations of website content.

 

International Congress of Parkinson’s Disease and Movement Disorders ®

Congress

Plenary Session 5208

Controversies in Movement Disorders

Thursday, October 8, 2026
10:00 - 11:00 | Grand Ballroom, Level 1

In this session, the faculty will provide arguments and counterarguments on topics for which there is a lack of consensus on interpretation of available evidence and the best path forward.

Chairs:

Roy Alcalay, Israel
Marina De Koning-Tijssen, Netherlands

Presenters:

Should we pursue implanted stem cells for symptomatic treatment? Yes
Claire Henchcliffe, USA

Should we pursue implanted stem cells for symptomatic treatment? No

Will emerging Alzheimer's disease therapies be useful in management of Parkinson's disease? Yes
Tamara Shiner, Israel

Will emerging Alzheimer's disease therapies be useful in management of Parkinson's disease? No
William Dauer, USA

CSPC Liaison(s):

Roy Alcalay, Israel

Learning Objectives

At the conclusion of this session, participants should be better able to:

  1. To identify the advantages and challenges in implanted stem cell therapy
  2. To recognize the promise and obstacles in using Alzheimer's disease therapy in Parkinson’s disease

Recommended Audience

Clinician / General Neurology
Fellow / Resident / Student
Health Professional (non-physician)
Industry
Researcher / Basic Science

Education Level

Advanced / Expert
Beginner / Foundational
Intermediate / Experienced